Nasus Pharma (NSRX) Current Deferred Tax Assets (2024 - 2025)

Nasus Pharma (NSRX) reported Current Deferred Tax Assets of $348000.0 for Q2 2025, up 33.85% quarter-over-quarter from $260000.0 in Q4 2024.

Nasus Pharma (NSRX) Current Deferred Tax Assets (2024 - 2025) Analysis & Trends

Nasus Pharma has reported Current Deferred Tax Assets for 2 years, with the latest figure at $348000.0 in Q2 2025.

For the quarter ending Q2 2025, Current Deferred Tax Assets changed N/A year-over-year to $348000.0; the trailing twelve-month figure through Jun 2025 stood at $348000.0 (changed N/A YoY), and the FY2024 full-year result was $260000.0, changed N/A from the prior year.
Current Deferred Tax Assets for Q2 2025 stood at $348000.0, up from $260000.0 in the prior quarter.
The five-year high for Current Deferred Tax Assets was $348000.0 in Q2 2025, with the low at $260000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn
10	Nasus Pharma	24.83 Mn	20.55 Mn	-

Download Data